BioSpace News Archive

Modern medicine depends on antibiotics to treat infections by disabling targets inside bacterial cells.

MedinCell today announces that its partner, Arthritis Innovation Corporation (AIC), who conducts and finances all development activities of F14 (MedinCell codename: mdc-CWM), has completed the patient enrollment in the first of two Phase 3 clinical studies of F14 in patients undergoing total knee replacement (TKR).

Gamma delta T cells, a special type of cell in the immune system, are incredibly effective at recognizing and killing cancer cells.

Metrodora Institute, an innovative medical and research center dedicated to advancing care, treatments, and cures for people living with complex, chronic diseases, announced that it has appointed John B. Wirthlin as Chief Executive Officer.

AbbVie today announced the 2023-2024 class of AbbVie Immunology Scholarship recipients.

MedMira Inc. has completed, with its Transfer Agent, the process and has received confirmation by the TSX.v as follows:.

Zylox-Tonbridge Medical Technology Co., Ltd. announced that its ZENFlow Tiger™ LD PTA Dilatation Catheter, a product independently developed by the Company, has received marketing approval from ANVISA.

Octave® Bioscience, Inc., a leading precision care company focused on delivering a new standard of care for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the publication of the successful clinical validation of the Octave® Multiple Sclerosis Disease Activity (MSDA) Test in the peer-reviewed journal Clinical Immunology.

Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, for the treatment of acute TBI.

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced that all five of the U.S.-based clinical sites participating in the conduct of the Phase 1 clinical trial of the Company’s lead investigational peptide drug conjugate, sudocetaxel zendusortide, are now activated to screen, enroll and dose advanced ovarian cancer patients.